Clinical Value of Hepatitis B Virus RNA Detection in Patients with Chronic Hepatitis B Infection

Objective: To study the clinical value of hepatitis B virus pregenomic RNA (HBV-pgRNA) detection in the treatment of hepatitis B. Methods: 60 patients with hepatitis B were included in the study. Serum HBV-pgRNA and HBV DNA levels in different phases of infection and during treatment were detected, and serum hepatitis B surface antigen (HbsAg) titer was detected by chemiluminescent immunoassay. DNA was extracted from liver biopsy tissue, and covalently closed circular DNA was detected to predict the therapeutic value in patients. Results: At the initial stage of treatment, the level of HBV-pgRNA in phase I, II, III, and IV showed a gradual decrease. Comparing the levels of HBV-pgRNA before and after treatment, we found that the level of HBV-pgRNA was significantly lower after treatment (P < 0.05). Among the indicators for predicting HBsAg seroconversion, the accuracy of HBV-pgRNA level was 85.0% (51/60). Conclusion: The clinical value of HBV-pgRNA detection in the treatment of hepatitis B is high.